Mad Money Uncovered...
Health Care: Drugs
AMAG Pharmaceuticals Inc. (AMAG: NASDAQ)
$24.58 -0.79 | -3.11%
05/20/13 - 02:05 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -16.75M | -77.07M | -81.15M | -93.35M |
| Operating Gains/Losses | 1.47M | 193.00K | -408.00K | -942.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -313.00K | -134.00K | 21.12M | -26.94M |
| (Increase) Decrease in Inventories | 5.89M | 1.51M | -6.68M | -9.06M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 9.68M |
| (Decrease) Increase In Payables | -12.20M | 1.70M | 2.74M | 13.22M |
| (Decrease) Increase In Other Current Liabilities | -405.00K | 0.00 | -294.00K | -68.00K |
| (Increase) Decrease In Other Working Capital | 7.91M | -6.70M | 46.70M | 0.00 |
| Other Non-Cash Items | 8.12M | 8.87M | 14.83M | 15.11M |
| Net Cash From Continuing Operations | -1.16M | -63.80M | -1.53M | -90.72M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -1.16M | -63.80M | -1.53M | -90.72M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -47.00K | -507.00K | -1.22M | -2.84M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 61.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -16.39M | 14.00M | -103.74M | 71.46M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 368.00K | 629.00K | 167.79M | 5.20M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 368.00K | 629.00K | 167.79M | 5.20M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -17.18M | -49.17M | 62.52M | -14.06M |
Portfolios with AMAG
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- UserPelican Watch
- UserPART 1 JPMorgan 28th Annual...
- UserPART 1 JPMorgan 27th Annual...
- Userileana
- UserShawen Portfolio 1
- Userfiallo Portfolio 1
Latest AMAG Headlines from TheStreet
- Ferumoxytol Results In Significant Hemoglobin Increases In Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed Or Could Not Tolerate Oral Iron Therapy 05.06.13 | 08:05 am
- Kudos To Keryx, But Can Zerenex Zing? 01.28.13 | 10:01 am
- 5 Stocks Ready to Break Out 01.18.13 | 12:01 pm
- 3 Unusual-Volume Stocks Moving Higher 11.01.12 | 02:11 pm
- AMAG Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.10.12 | 03:09 pm
- AMAG Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.26.12 | 11:07 am
- AMAG Pharmaceuticals' CEO Presents IDA-301 Data (Transcript) 07.20.12 | 01:07 am
- 8 Stocks Rising on Huge Volume 04.20.12 | 01:04 pm
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Insiders Trading AMAG, CLWR, GTXI 03.06.12 | 10:03 am
Press Releases for AMAG
- AMAG Pharmaceuticals Announces Positive Preliminary Results From An Extension Study Evaluating The Safety And Efficacy Of Repeat Dosing With Ferumoxytol In Patients With Persistent Or Recurring Iron Deficiency Anemia, Regardless Of The Underlying Cause - Business Wire 03.15.13 | 06:03 am
- AMAG Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Feraheme Label Expansion To Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron - Business Wire 03.06.13 | 08:03 am
- AMAG Announces Fourth Quarter And Year End 2012 Financial Results - Business Wire 03.01.13 | 08:03 am
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Healthcare Conferences - Business Wire 02.21.13 | 04:02 pm
- Branham Law, LLP Investigates AMAG Pharmaceuticals On Behalf Of Stockholders - Business Wire 02.11.13 | 04:02 pm
- AMAG Pharmaceuticals, Inc. To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 05:02 pm
- AMAG Pharmaceuticals Provides Business Update Announces Preliminary 2012 Financial Results And 2013 Financial Guidance - Business Wire 01.06.13 | 07:01 am
- AMAG Pharmaceuticals Appoints Greg Madison As Chief Commercial Officer - Business Wire 01.02.13 | 08:01 am
- AMAG Pharmaceuticals, Inc. To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.26.12 | 08:12 am
- AMAG Pharmaceuticals Announces FDA Submission Of A Supplemental New Drug Application For Feraheme - Business Wire 12.24.12 | 08:12 am
Partner Headlines for AMAG
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.10.12 | 09:10 am
- AMAG Beats Expectations - Analyst Blog - Zacks 08.01.12 | 09:08 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 07.27.12 | 09:07 am
- Akamai Tech REITERATED at Hold and 2 Must-See Reiterated Ratings - Wall St. Cheat Sheet 07.26.12 | 02:07 am
- AMAG Beats Riding on Feraheme Sales - Analyst Blog - Zacks 05.02.12 | 10:05 am
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- Israel Englander's Stock Picks With Insider Purchases - Seeking Alpha 01.18.12 | 09:01 am
- 17 Breakout Stocks Boosted By Insiders - Seeking Alpha 12.30.11 | 04:12 pm
- McNicoll Lewis & Vlak Raises PT on AMAG Pharmaceuticals to $23 - Benzinga 12.12.11 | 01:12 pm
